Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ASP Isotopes Inc. (NASDAQ: ASPI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on ASP Isotopes’ activities as a development stage advanced materials company focused on isotope enrichment technologies, as well as the work of its subsidiaries in nuclear fuels, helium, and related areas.
Through current reports on Form 8-K, ASP Isotopes discloses material events such as the closing of its acquisition of Renergen Limited, a helium and liquefied natural gas producer with operations at the Virginia Gas Project in South Africa. Other 8-K filings describe regulatory approvals for that transaction, private placements of convertible notes issued by its subsidiary Quantum Leap Energy LLC to fund laser enrichment production facilities, and confidential submission of a draft registration statement for a proposed initial public offering of Quantum Leap Energy’s Class A common stock.
The company’s 8-K filings also cover regulatory engagement in the United Kingdom by Quantum Leap Energy Ltd regarding potential High-Assay Low Enriched Uranium (HALEU) production, as well as the acquisition of assets from One 30 Seven Inc. to develop Creber Units for processing water-soluble nuclear waste. These documents provide formal descriptions of transaction terms, use of proceeds, conversion mechanics for notes, and related risk and disclosure language.
ASP Isotopes’ definitive proxy statement on Schedule 14A outlines governance matters, including the annual meeting agenda, director elections, auditor ratification, and voting procedures. The proxy materials also describe the company’s status as an emerging growth company and provide information on its capital structure and shareholder voting rights.
On Stock Titan, investors can use AI-powered tools to read summaries of these filings, quickly identify key sections, and navigate to specific topics such as capital raises, acquisitions, nuclear fuel cycle initiatives, or governance changes. Real-time updates from EDGAR ensure that new 8-Ks, proxy statements, and other relevant filings for ASPI are available as they are published, helping users follow how ASP Isotopes documents its strategic transactions, financing activities, and regulatory developments.
ASP Isotopes Inc. entered into an underwriting agreement to sell 17,167,380 shares of common stock at $11.65 per share. The underwriters have a 30‑day option to purchase up to 2,575,106 additional shares at the same price.
Gross proceeds are expected to be approximately $210.3 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions. The sale is being made under the company’s effective Form S‑3 registration statement with a related prospectus and prospectus supplement. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are acting as underwriters.
ASP Isotopes (ASPI) Form 4: Interim CEO and COO reported a sale of 22,500 shares of common stock on 10/14/2025 at a weighted average price of $13.599. The filing states these were “sell to cover” transactions executed under a Rule 10b5‑1 trading plan adopted on June 9, 2025 to cover tax withholding tied to vesting of restricted stock awards.
Trades occurred across multiple executions at prices ranging from $12.31 to $14.46. Following the transactions, the reporting person beneficially owns 1,647,193 shares directly.
ASP Isotopes Inc. (ASPI) launched a preliminary prospectus supplement for a primary underwritten offering of common stock on Nasdaq. Cantor Fitzgerald & Co. and Lucid Capital Markets, LLC are joint bookrunning managers. The underwriters have a 30‑day option to purchase additional shares. Net proceeds are intended for general corporate purposes, including working capital, operating expenses, and capital expenditures, and may also support complementary acquisitions (with no binding commitments).
ASPI’s stock last closed at $13.32 on October 13, 2025. Shares outstanding were 93,406,629 as of October 10, 2025; this is a baseline figure, not the amount being offered. The company reported $67.7 million in cash and cash equivalents as of June 30, 2025, and raised $56.3 million in net proceeds in July 2025. Lock‑ups apply following closing: company 90 days; executive officers 60 days plus 30 days; directors 30 days plus 30 days, subject to stated exceptions.
ASP Isotopes Inc. reported business updates via Form 8-K. The company announced a supply agreement for enriched silicon-28 and the acquisition of a radiopharmacy in the United States. A press release with details is furnished as Exhibit 99.1.
Todd Wider, a director of ASP Isotopes Inc. (ASPI), executed equity transactions on 09/14/2025 and 09/15/2025. He acquired 96,000 shares through exercise of stock options with a conversion/exercise price of $2, and the reported ownership following that transaction was 806,230 shares. The filing also reports 21,892 shares withheld to satisfy option exercise-related obligations at an average price of $8.77, and a sale of 74,108 shares on 09/15/2025 at a weighted average price of $8.7551, leaving beneficial ownership of 710,230 shares after the reported transactions.
ASP Isotopes (ASPI) announced a leadership transition. Effective October 1, 2025, founder Paul Mann became Executive Chairman and began a temporary leave from Chief Executive Officer duties for health reasons. The Board appointed Chief Operating Officer Robert Ainscow as Interim CEO (principal executive officer) in addition to his current role.
Mr. Mann will guide strategy and support senior management alongside the Board, while Mr. Ainscow will manage CEO direct reports and external communications. The company made no new employment arrangements for Robert Ainscow. The filing notes Robert is the brother of Donald Ainscow, EVP, General Counsel and Secretary, whose compensation includes a base salary of $425,000 and an initial grant of 400,000 shares vesting over four years.
ASP Isotopes Inc. reported that it has received a purchase order for enriched Barium-137 from a U.S.-based customer. This order relates to the company’s specialized isotope products and reflects commercial demand from a domestic buyer.
The company communicated this development through a press release dated September 30, 2025, which is included as an exhibit to this report for investors seeking additional operational detail.
ASP Isotopes Inc. filed a Form 8-K to report that it issued a press release on September 29, 2025 announcing changes to the executive management teams of ASP Isotopes Inc. and its subsidiary, Quantum Leap Energy LLC, effective October 1, 2025. The press release describing these leadership changes is included as Exhibit 99.1 and incorporated by reference, except for its third through seventh paragraphs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has become the controlling shareholder of Skyline Builders Group Holding Limited (SKBL), a Cayman Islands company listed on Nasdaq under “SKBL”. QLE plans to use SKBL to pursue acquisitions of critical materials supply-chain assets that it believes are important for U.S. security and QLE’s long-term growth.
On August 27, 2025, QLE bought all 1,995,000 Class B Ordinary Shares of SKBL from the prior controller for $1,000,000. Each Class B share carries 20 votes, compared with one vote for each Class A share. On August 29, 2025, SKBL completed a Private Placement, issuing 1,359,314 Class A shares plus multiple series of warrants and receiving $17,775,000 in gross proceeds. QLE invested $1,500,000 for Class A shares and warrants, while about $7,000,000 of the proceeds were used to retire 18,500,000 Class A shares held by the former controlling shareholder.
After these steps, QLE holds 79.14% of the aggregate voting power of SKBL and therefore controls the company. ASP Isotopes’ Chairman and CEO, Paul Mann, separately invested $2,500,000 personally in SKBL shares and warrants, subject to a 4.99% beneficial ownership cap on warrant exercises.
ASP Isotopes Inc. has extended the deadline to complete its planned acquisition of Renergen Limited, giving more time to meet closing conditions. Under the proposed South African scheme of arrangement, Renergen shareholders would receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date.
The longstop date has been moved from September 30, 2025 to November 28, 2025 to obtain remaining regulatory approval and third-party consents. Implementation of the scheme still depends on approval from the Financial Surveillance Department of the South African Reserve Bank, and both companies continue to work toward timely approval.
FAQ
What is the current stock price of ASP Isotopes (ASPI)?
What is the market cap of ASP Isotopes (ASPI)?
